Literature DB >> 20202841

Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists.

Nicole R Miller1, R Nathan Daniels, David Lee, P Jeffrey Conn, Craig W Lindsley.   

Abstract

This Letter describes the synthesis and SAR, developed through an iterative analog library approach, of a novel series of selective M(1) mAChR antagonists, based on an N-(4-(4-alkylpiperazin-1-yl)phenyl)benzamide scaffold for the potential treatment of Parkinson's disease, dystonia and other movement disorders. Compounds in this series possess M(1) antagonist IC(50)s in the 350 nM to >10 microM range with varying degrees of functional selectivity versus M(2)-M(5). 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202841      PMCID: PMC2843780          DOI: 10.1016/j.bmcl.2010.02.041

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  Muscarinic receptor ligands and their therapeutic potential.

Authors:  R M Eglen; A Choppin; M P Dillon; S Hegde
Journal:  Curr Opin Chem Biol       Date:  1999-08       Impact factor: 8.822

2.  Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries.

Authors:  William Leister; Kimberly Strauss; David Wisnoski; Zhijian Zhao; Craig Lindsley
Journal:  J Comb Chem       Date:  2003 May-Jun

3.  Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists.

Authors:  L Michelle Lewis; Douglas Sheffler; Richard Williams; Thomas M Bridges; J Phillip Kennedy; J T Brogan; Matthew J Mulder; Lyndsey Williams; Natalia T Nalywajko; Colleen M Niswender; Charles D Weaver; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

4.  A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning.

Authors:  Douglas J Sheffler; Richard Williams; Thomas M Bridges; Zixiu Xiang; Alexander S Kane; Nellie E Byun; Satyawan Jadhav; Mathew M Mock; Fang Zheng; L Michelle Lewis; Carrie K Jones; Colleen M Niswender; Charles D Weaver; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2009-04-30       Impact factor: 4.436

5.  The relative selectivity of anticholinergic drugs for the M1 and M2 muscarinic receptor subtypes.

Authors:  R E Burke
Journal:  Mov Disord       Date:  1986       Impact factor: 10.338

6.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

7.  Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies.

Authors:  N J Birdsall; T Farries; P Gharagozloo; S Kobayashi; S Lazareno; M Sugimoto
Journal:  Mol Pharmacol       Date:  1999-04       Impact factor: 4.436

Review 8.  Muscarinic toxins from the green mamba.

Authors:  K N Bradley
Journal:  Pharmacol Ther       Date:  2000-02       Impact factor: 12.310

9.  Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.

Authors:  Silvia Dei; Cristina Bellucci; Michela Buccioni; Marta Ferraroni; Luca Guandalini; Dina Manetti; Elisabetta Martini; Gabriella Marucci; Rosanna Matucci; Marta Nesi; Maria Novella Romanelli; Serena Scapecchi; Elisabetta Teodori
Journal:  J Med Chem       Date:  2007-02-17       Impact factor: 7.446

10.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

View more
  2 in total

1.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

2.  Discovery of PIPE-359, a Brain-Penetrant, Selective M1 Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.

Authors:  Thomas O Schrader; Yifeng Xiong; Ariana O Lorenzana; Alexander Broadhead; Karin J Stebbins; Michael M Poon; Christopher Baccei; Daniel S Lorrain
Journal:  ACS Med Chem Lett       Date:  2020-12-24       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.